Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

September 21, 2022

Study Completion Date

September 21, 2022

Conditions
Covid19
Interventions
DRUG

Tempol

Tempol 800 mg capsule will be administered at 400mg (2 capsules) two times daily for fourteen (14) consecutive days.

OTHER

Placebo

Placebo capsules will be administered orally (2 capsules) two times daily for fourteen (14) consecutive days.

Trial Locations (17)

23707

Meridian Clinical Research, Portsmouth

28112

Monroe Biomedical Research, Monroe

32607

Sarkis Clinical Trials, Gainesville

32808

Omega Research Orlando, LLC, Orlando

33166

Doral medical Research, Doral

33325

Sunrise Research Institute, Sunrise

36207

Pinnacle Research Group, Anniston

37067

Clinical Trials Center of Middle Tennessee, LLC, Franklin

45406

Dayton Clinical Research, Dayton

46143

Center for Respiratory and Sleep Medicine, Greenwood

68128

Barrett Clinical, La Vista

70072

Tandem Clinical Research GI, LLC., Marrero

77017

Vilo Research Group, Houston

77091

United Memorial Medical Center, Houston

77494

R&H Clinical Research, Katy

90057

LA Universal Research, Los Angeles

98052

Eastside Research Associates, Redmond

All Listed Sponsors
lead

Adamis Pharmaceuticals Corporation

INDUSTRY

NCT04729595 - Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients. | Biotech Hunter | Biotech Hunter